Amgen (NASDAQ:AMGN) Shares Bought Rep. Marjorie Taylor Greene

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on October 28th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on October 24th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of MercadoLibre (NASDAQ:MELI) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Blackstone (NYSE:BX) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Cardinal Health (NYSE:CAH) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Kinder Morgan (NYSE:KMI) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Palo Alto Networks (NASDAQ:PANW) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of iShares Bitcoin Trust ETF (NASDAQ:IBIT) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Occidental Petroleum (NYSE:OXY) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 10/24/2025.

Amgen Trading Up 0.1%

Shares of AMGN stock opened at $292.00 on Friday. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The firm has a market cap of $157.20 billion, a P/E ratio of 23.88, a PEG ratio of 2.61 and a beta of 0.49. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $335.88. The firm’s 50-day simple moving average is $287.66 and its 200-day simple moving average is $287.48.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. The company had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. Amgen’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Institutional Investors Weigh In On Amgen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Westfuller Advisors LLC acquired a new position in shares of Amgen in the third quarter worth about $81,000. Delta Financial Advisors LLC raised its position in shares of Amgen by 1.5% in the 3rd quarter. Delta Financial Advisors LLC now owns 9,894 shares of the medical research company’s stock valued at $2,792,000 after purchasing an additional 146 shares in the last quarter. Tranquilli Financial Advisor LLC raised its position in shares of Amgen by 10.7% in the 3rd quarter. Tranquilli Financial Advisor LLC now owns 808 shares of the medical research company’s stock valued at $228,000 after purchasing an additional 78 shares in the last quarter. JLB & Associates Inc. raised its holdings in Amgen by 1.1% in the third quarter. JLB & Associates Inc. now owns 67,092 shares of the medical research company’s stock valued at $18,933,000 after acquiring an additional 737 shares in the last quarter. Finally, Rossmore Private Capital raised its holdings in Amgen by 10.4% in the third quarter. Rossmore Private Capital now owns 4,472 shares of the medical research company’s stock valued at $1,262,000 after acquiring an additional 421 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AMGN. Piper Sandler raised their price objective on Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a report on Monday, August 25th. Raymond James Financial initiated coverage on shares of Amgen in a report on Wednesday, September 3rd. They issued a “market perform” rating on the stock. Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Morgan Stanley raised their price objective on Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Finally, UBS Group cut their price objective on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Six research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $300.94.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the sale, the senior vice president owned 7,209 shares in the company, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.76% of the company’s stock.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.